Related Experiment Video
Updated: May 1, 2026
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
[Clinical evaluation of lapatinib therapy in metastatic breast cancer using the Bayes meta-analysis]
Tadao Inoue1, Tomokazu Iyoda, Wataru Yamamoto
1Dept. of Hospital Administration, Tokyo Women's Medical University.
Abstract:
The efficacy of treatments involving lapatinib for patients with metastatic breast cancers was evaluated in a Bayesian metaanalysis of published data from randomized controlled clinical trials. Four randomized controlled trials including 2,708 patients met the inclusion criteria. Among these patients, 568 were positive for the human epidermal growth factor receptor 2(HER2). The clinical benefit rate(CBR)for HER2-positive patients was the primary outcome of the analysis, and the overall survival(l OS) and the number needed to treat(NNT)were the secondary outcomes of the reported meta-analysis. The Bayesian metaanalysis was conducted according to the Markov-chain Monte-Carlo technique in WinBUGS. The CBR for HER2-positive patients was significantly improved(odds ratio[OR]: 2.281, 95% confidence interval[CI]: 1.490-3.628), whereas no statistically significant improvement was seen in the overall patient CBR(OR: 1.559, 95% CI: 0.768-3.238). The OS hazard ratio (HR)and NNT for the CBR were also estimated for HER2-positive patients. The difference in the OS HR was not statistically significant(HR: 0.789, 95% CI: 0.556-1.086)for HER2-positive patients. The improvement in the NNT for the CBR was statistically significant(NNT 5.164, 95% CI: 3.803-8.723)for HER2-positive patients.
Insights
Lapatinib treatment significantly improved clinical benefit rates in HER2-positive metastatic breast cancer patients. Overall survival showed no significant change, but the number needed to treat for clinical benefit was statistically improved.
Area of Science:
- Oncology
- Pharmacology
- Biostatistics
Background:
- Metastatic breast cancer (MBC) poses a significant clinical challenge.
- Targeted therapies, such as lapatinib, are crucial for managing HER2-positive MBC.
- Evaluating treatment efficacy requires robust meta-analysis of clinical trial data.
Purpose of the Study:
- To evaluate the efficacy of lapatinib in patients with metastatic breast cancer.
- To specifically assess outcomes in human epidermal growth factor receptor 2 (HER2)-positive patients.
- To determine the impact on clinical benefit rate (CBR), overall survival (OS), and number needed to treat (NNT).
Main Methods:
- A Bayesian meta-analysis of published data from four randomized controlled trials (RCTs) involving 2,708 patients.
- Focus on 568 HER2-positive patients.
- Markov-chain Monte-Carlo technique utilized in WinBUGS for analysis.
Main Results:
- Lapatinib significantly improved the clinical benefit rate (CBR) in HER2-positive patients (odds ratio [OR]: 2.281, 95% confidence interval [CI]: 1.490-3.628).
- No statistically significant improvement in CBR was observed for the overall patient population (OR: 1.559, 95% CI: 0.768-3.238).
- Overall survival (OS) hazard ratio (HR) was not statistically significant for HER2-positive patients (HR: 0.789, 95% CI: 0.556-1.086), but the number needed to treat (NNT) for CBR showed significant improvement (NNT: 5.164, 95% CI: 3.803-8.723).
Conclusions:
- Lapatinib demonstrates significant efficacy in improving clinical benefit rates for HER2-positive metastatic breast cancer patients.
- While OS did not show a statistically significant improvement, the reduced NNT suggests a positive impact on treatment efficiency.
- The findings support the use of lapatinib as a targeted therapy for HER2-positive MBC, warranting further investigation into its long-term survival benefits.
Related Concept Videos
01:21Cancer Survival Analysis
01:24Kaplan-Meier Approach